Surprisingly, despite the high prevalence of CD8+/PD-1+ T-cells in NASH-driven HCCs these tumours do not respond to anti-PD-1 therapy which instead promotes an earlier HCC onset. This evidence concerns the gene PDCD1 and metabolic dysfunction-associated steatohepatitis.